QL1706 Plus Lenvatinib

Phase 2Small molecule

QL1706 Plus Lenvatinib is one of 71 small molecule programs targeting Hepatocellular Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatocellular CarcinomaActive, not recruiting

Renal Cell CarcinomaActive, not recruiting

Hepatocellular CarcinomaPhase 2

Active, not recruiting

Renal Cell CarcinomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

797 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Sovaldi

Gilead

Preclinical

1 2

QL1706 Plus Lenvatinib

Qilu Pharmaceutical Co., Ltd.

Phase 2

1 3

Apatinib

LLaNova Medicines Zhejiang Co., Ltd.

Preclinical

16 4

Doptelet

AAkarx

Preclinical

1 5

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 6

Vermox

WWim Janssens

Preclinical

1 7

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 8

Opdivo

Bristol-Myers Squibb

Preclinical

2 9

Anlotinib

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Preclinical

5 10

Alcohol

Astellas

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Not yet recruiting

Hepatocellular Carcinoma

NCT06884982

Clinical

Trials by Indication[1]

Renal Cell Carcinoma1 trial

A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC)

Unknown status· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 1/2·NCT05262413·60 enrolled

Hepatocellular Carcinoma1 trial

An Exploratory Clinical Study on Neoadjuvant Treatment of Hepatocellular Carcinoma with QL1706 Combined with Lenvatinib

Not yet recruiting·NNorthern Jiangsu People's Hospital·Phase 2·NCT06884982·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for QL1706 Plus Lenvatinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — QL1706 Plus Lenvatinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for QL1706 Plus Lenvatinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Qilu Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Qilu Pharmaceutical Co., Ltd.

QL1706 Plus Lenvatinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Renal Cell Carcinoma1 trial

Hepatocellular Carcinoma1 trial

References

Drug Info

Quick Facts

Related News